A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas

Oncology

Volumn 70, Issue 2, 2006, Pages 134-140

  Ducreux, M P ^a   Boige, V ^a   Leboulleux, S ^a   Malka, D ^a   Kergoat, P ^a   Dromain, C ^a   Elias, D ^a   De Baere, T ^a   Sabourin, J C ^a   Duvillard, P ^a   Lasser, P ^a   Schlumberger, M ^a   Baudin, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Camptothecin; Drug therapy; Irinotecan; Neuroendocrine tumors

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; PACLITAXEL; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GASTROENTEROPANCREATIC WELL DIFFERENTIATED ENDOCRINE CARCINOMA; HUMAN; INTESTINE CARCINOMA; LUNG CARCINOMA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; ENTEROENDOCRINE CELLS; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33646769634     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093004     Document Type: Article

References (24)

1. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355.
2. Moertel CG, Kvols LK, O'Connell MJ, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.
3. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D: Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-523.
4. Cheng PN, Saltz LB: Failure to confirm major objective antitumor activity for streptozotocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-948.
5. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? Eur J Cancer 2004;40:515-520.
6. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J: A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001;91:1543-1548.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
8. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-939.
9. Arnold R: Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505.
10. Baudin E, Bidart JM, Rougier P, Lazar V, Ruffie P, Ropers J, Ducreux M, Troalen F, Sabourin JC, Comoy E, Lasser P, DeBaere T, Schlumberger M: Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 1999;84:69-75.
11. Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffie P, Schlumberger M: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998;78:1102-1107.
12. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-449.
13. Murray-Lyon IM, Eddleston ALWF, Williams R, Brown M, Hogbin BM, Bennett A,Edwards JC, Taylor KW: Treatment of multiple hormone-producing malignant islet cell tumours with streptozotocin. Lancet 1968;ii:895-898.
14. Moertel CG, Hanley JA, Johnsson LA: Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980;303:1189-1194.
15. Moertel CG: An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-1522.
16. Moertel CG, Lavin P, Hahn G: Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Cancer Treat Rep 1987;66:1567-1569.
17. Haller DG, Schutt A, Dayal Y, Ryan L, Lipsitz S: Chemotherapy for metastatic tumors: an ECOG phase II-III trial. Proc Am Soc Clin Oncol 1990;9:102.
18. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J, Kunselman S: The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-309.
19. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107.
20. Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar LA, Morganti A, Gruia G, Miller L, Green MR: A randomized phase 3 study comparing efficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients (pts) with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc Am Soc Clin Oncol 2003;22:251.
21. Baker J, Schnirer II, Yao JC, Carr K, Ho L, Ajani JA: Phase II trial of irinotecan in patients with advanced carcinoid tumor. Proc Am Soc Clin Oncol 2002;21:166a.
22. Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, Mahjoubi M, Méry-Mignard D, Rougier P: Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-2908.
23. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
24. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.